The viability of cryopreserved PBPC depends on the DMSO concentration and the concentration of nucleated cells in the graft

References

• Goldman JM, Th'ng KH, Park DS, et al. Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukaemia in blast-cell transformation. Br J Haematol 1978; 40: 185–95
   PubMed Web of Science ®Google Scholar
• Davis JM, Rowley SD, Braine HG, et al. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990; 75: 781–6
   PubMed Web of Science ®Google Scholar
• Stroncek DF, Fautsch SK, Lasky LC, et al. Adverse reactions in patients transfused with cryopreserved marrow. Transfusion 1991; 31: 521–6
   PubMed Web of Science ®Google Scholar
• Zambelli A, Poggi G, Da Prada G, et al. Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res 1998; 6B: 4705–8
   Google Scholar
• Svane IM, Homburg KM, Kamby C, et al. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer: a quality assessment study. Acta Oncol 2002; 41: 675–83
   PubMed Web of Science ®Google Scholar
• Curcoy AI, Alcorta I, Estella J, et al. Cryopreservation of HPCs with high cell concentration in 5-percent DMSO for transplantation to children. Transfusion 2002; 42: 962
   PubMed Web of Science ®Google Scholar
• Law P, Ball ED, Mullen M. Post-thaw washing of human peripheral blood progenitor cell (PBPC) and cord blood (CB) units. Blood 2000; 96: 378–81
   Google Scholar
• Lakota J, Fuchsberger P. Autologous stem cell transplantation with stem cells preserved in the presence of 4.5 and 2.2% DMSO. Bone Marrow Transplant 1996; 18: 262–3
   PubMed Web of Science ®Google Scholar
• Katayama Y, Yano T, Bessho A, et al. The effects of a simplified method for cryopreservation and thawing procedures on peripheral blood stem cells. Bone Marrow Transplant 1997; 19: 283–7
   PubMed Web of Science ®Google Scholar
• Halle P, Tournilhac O, Knopinska-Posluszny W, et al. Uncontrolled-rate freezing and storage at −80 degrees C, with only 3.5-percent DMSO in cryoprotective solution for 109 autologous peripheral blood progenitor cell transplantations. Transfusion 2001; 41: 667–73
   PubMed Web of Science ®Google Scholar
• Rowley SD, Feng Z, Chen L, et al. A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch. Bone Marrow Transplant 2003; 31: 1043–51
   PubMed Web of Science ®Google Scholar
• Donaldson C, Armitage WJ, Denning-Kendall PA, et al. Optimal cryopreservation of human umbilical cord blood. Bone Marrow Transplant 1996; 18: 725–31
   PubMed Web of Science ®Google Scholar
• Beaujean F, Bourhis JH, Bayle C, et al. Successful cryopreservation of purified autologous CD34+ cells: influence of freezing parameters on cell recovery and engraftment. Bone Marrow Transplant 1998; 22: 1091–6
   PubMed Web of Science ®Google Scholar
• Richter E, Eichler H, Raske D, et al. 5% Me2SO is sufficient to preserve stem cells derived from cord blood. Bone Marrow Transplant 1998; 22(Suppl 1)16
   Google Scholar
• Szmant HH. Physical properties of dimethyl sulfoxide and its function in biological systems. Ann NY Acad Sci 1975; 243: 20–3
   PubMed Web of Science ®Google Scholar
• Branch DR, Calderwood S, Cecutti MA, et al. Hematopoietic progenitor cells are resistant to dimethyl sulfoxide toxicity. Transfusion 1994; 34: 887–90
   PubMedGoogle Scholar
• Abrahamsen JF, Bakken AM, Bruserud O. Cryopreserving human peripheral blood progenitor cells with 5-percent rather than 10-percent DMSO results in less apoptosis and necrosis in CD34+ cells. Transfusion 2002; 42: 1573–80
   PubMed Web of Science ®Google Scholar
• Bakken AM, Bruserud O, Abrahamsen JF. No difference in colony formation of peripheral blood stem cells frozen with 5% or 10% DMSO. J Hematother Stem Cell Res 2003; 12: 351–8
   PubMedGoogle Scholar
• Abrahamsen JF, Rusten L, Bakken AM, et al. Better preservation of early hematopoietic progenitor cells when human peripheral blood progenitor cells are cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent dimethylsulfoxide. Transfusion 2004; 44: 785–9
   PubMed Web of Science ®Google Scholar
• Keeney M, Chin-Yee I, Weir K, et al. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998; 34: 61–70
   PubMedGoogle Scholar
• Yang H, Acker JP, Hannon J, et al. Damage and protection of UC blood cells during cryopreservation. Cytotherapy 2001; 3: 377–86
   PubMed Web of Science ®Google Scholar
• Galmes A, Besalduch J, Bargay J, et al. Long-term storage at −80 degrees C of hematopoietic progenitor cells with 5-percent dimethyl sulfoxide as the sole cryoprotectant. Transfusion 1999; 39: 70–3
   PubMed Web of Science ®Google Scholar
• Rowley SD, Bensinger WI, Gooley TA, et al. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994; 83: 31–6
   Google Scholar
• Abrahamsen JF, Wentzel-Larsen T, Bruserud O. The viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2×106 CD34+ cells/kg. Cytotherapy 2004; 6: 356–62
   PubMed Web of Science ®Google Scholar